KM Research Hub

REVIEW LEDGER

论文复核台

集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。

论文元数据入排图像/No. at risk 复核依据
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.PMID 42127535 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer.PMID 42166701 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.PMID 42167105 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial.PMID 42202843 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.PMID 42214243 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.PMID 42296979 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.PMID 42308688 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial.PMID 42372745 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.PMID 42418739 · 2026-Juleligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial.PMID 42214392 · 2026-Jun-27eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.PMID 42218899 · 2026-Jun-27eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 - metastatic breast cancer: A translational analysis of the GEICAM/2013-02 PEARL trial.PMID 42202479 · 2026-Jun-25eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
First-line atezolizumab monotherapy vs . single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation.PMID 41424028 · 2026-Jun-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.PMID 41980234 · 2026-Jun-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.PMID 42217458 · 2026-Jun-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study.PMID 42225112 · 2026-Jun-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.PMID 41911073 · 2026-Jun-18eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.PMID 41915772 · 2026-Jun-18eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
[177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial.PMID 42142431 · 2026-Jun-18eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation.PMID 41915435 · 2026-Jun-15eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial.PMID 41770817 · 2026-Jun-11eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.PMID 41369677 · 2026-Jun-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.PMID 41758929 · 2026-Jun-04eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial.PMID 41967349 · 2026-Jun-03eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.PMID 42019226 · 2026-Jun-03eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group.PMID 41285272 · 2026-Jun-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors.PMID 41504634 · 2026-Jun-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Hypofractionated Versus Normofractionated Accelerated Radiation Therapy With or Without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO): A Randomized, Open-Label, Phase 3, Noninferiority Trial.PMID 41711624 · 2026-Jun-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.PMID 41837753 · 2026-Jun-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.PMID 42060297 · 2026-Jun-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.PMID 42295761 · 2026-Jun-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).PMID 41073155 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109.PMID 41535566 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.PMID 41571045 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial.PMID 41621752 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.PMID 41687718 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Randomized phase III Study of Adding Paclitaxel to Chemoradiotherapy With Capecitabine and Mitomycin C in Squamous Cell Anal Carcinoma.PMID 41688329 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial.PMID 41690366 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.PMID 41720427 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.PMID 41739398 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.PMID 41896648 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.PMID 41990300 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.PMID 41996761 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.PMID 42000139 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI).PMID 42107198 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma.PMID 42108156 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS).PMID 42308452 · 2026-Juneligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.PMID 42202319 · 2026-May-28eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.PMID 42168151 · 2026-May-22eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603.PMID 41564372 · 2026-May-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。